Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-207

from the information from the link

"...…. the purchase of the assets of the CardioCel, CardioCel 3D, CardioCel Neo, VascuCel, and VascuCel 3D biologic patch business...…."

"......The License Agreement restricts the Company’s use of the licensed technology and intellectual property to: patches for cardiac repair or replacement (excluding catheter-delivered repair or catheter-delivered replacement devices), conduits formed from flat patches for cardiac repair or replacement, and vascular repair or replacement...……... and patches for surgical leaflet repair or replacement...."

"....the Company may not use the licensed technology or intellectual property with its XenoSure product line...."

Not sure that we have 'given the CC range away'. and while the company has basically all of the marketable products, it is limited to how they can be used. like the apple and the tree analogy...……...we have the tree and we have sold the apples, but only to be used for eating.....not for making juice, brandy or apple pies, turnovers, strudel etc.......nothing else...… just for eating...…..

From the website, Lemaitre appear to be more vascular focussed than cardiac...…….. so not a current competitor in the cardiac repair space, nor the valve replacement...……. Not sure what this really means, but they wont likely be a competitor in the mitral or aortic valve space anytime soon......maybe a deciding factor in the deal making by WP et al......

Just my 2 cents worth.

have a nice day.